| 摘要 |
(I) Compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof wherein R1, R2 and R3 are as herein defined; R4 is a substitutent as herein defined or both R4 groups form a ring together with the carbon atoms to which they are attached to form a fused bicyclic ring containing from 8 to 12 atoms which may be saturated or unsaturated provided that when R1 is a substituted or unsubstituted pyrazolyl then R4 is not H and where both adjacent R4 groups form a ring with the atoms to which they are attached the adjacent R4 groups do not form an unsaturated carbocyclic ring with 6 carbon atoms; when R1 is a substituted or unsubstituted C6-10aryl then R4 is not H or methyl and where both adjacent R4 groups form a ring with the atoms to which they are attached the adjacent R4 groups do not form an unsaturated carbocyclic ring with 6 carbon atoms; and when R1 is a substituted or unsubstituted pyridyl then R4 is not methyl. The compound 4-fluoro-N-[[1-[4-(2-methylpyrazol-3-yl)phthalazin-1-yl]pyrrolidin-3-yl]methyl]-2-(trifluoromethyl)benzamide is also provided. The compounds of formula (I) are useful as inhibitors in the hedgehog signalling pathway, particularly Smoothened (Smo) in the treatment of cancer. |
